Redhill Biopharma (RDHL) Earning Somewhat Favorable News Coverage, Report Finds
Press coverage about Redhill Biopharma (NASDAQ:RDHL) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Redhill Biopharma earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.1885938232709 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s analysis:
- RedHill Biopharma (RDHL) Reports 2017 Year-End Business Update – StreetInsider.com (streetinsider.com)
- RedHill makes cutbacks, gives up migraine product (globes.co.il)
- BRIEF-Redhill Biopharma provides 2017 year-end business update (RDHL) (markets.businessinsider.com)
- RedHill Biopharma Provides 2017 Year-End Business Update – GlobeNewswire (press release) (globenewswire.com)
Redhill Biopharma (NASDAQ:RDHL) opened at $4.63 on Friday. Redhill Biopharma has a 1 year low of $4.30 and a 1 year high of $11.99.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Stock Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related stocks with our FREE daily email newsletter.